Yo pasaba por aquí a ver qué contabais... Esto es de ayer noche.
Novavax to Present Clinical Data on RSV F and NanoFlu™ Vaccines at World Vaccine Congress
it will present on its two lead vaccine programs at the World Vaccine Congress, April 2-5 in Washington, D.C. These presentations include details from the Phase 3 Prepare™ trial of its RSV F vaccine for infants via maternal immunization, as well as positive results from the Phase 1/2 trial of NanoFlu recombinant influenza vaccine, including its proprietary Matrix-M™ adjuvant, in older adults.
RSV F Vaccine Maternal Immunization Program
it will reach approximately 4,600 participants, including approximately 3,000 actively vaccinated mothers, in the
second quarter of 2018, which will enable an
interim efficacy analysis with results reported in
early 2019
Details for the two presentations are as follows:
Title: “The RSV F nanoparticle vaccine for infants via maternal immunization in Phase 3: rationale and update”
Date and Time: Wednesday, April 4, 11:40 a.m.
Presenter: Gregory M. Glenn, M.D., President of Research and Development, Novavax
Title: “Novavax NanoFlu vaccine induced improved immune responses against homologous and drifted A/H3N2 viruses in older adults compared to egg-based, high-dose, influenza vaccine”
Date and Time: Wednesday, April 4, 3:55 p.m.
Presenter: Vivek Shinde, M.D., Director of Clinical Development, Novavax
«Después de nada, o después de todo/ supe que todo no era más que nada.»